{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Summarized for each cohort using the Kaplan-Meier method.","groups":[{"description":"Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Trametinib)"},{"description":"Patients who develop progressive disease on trametinib monotherapy or achieve less then a PR after 4 cycles of treatment will have the option to continue on trametinib with the addition of GSK2141795","id":"OG001","title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"populationDescription":"Not reported. Data were not collected and not analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From time measurement criteria are met for CR or PR (complete or partial response), (whichever recorded first) until first date that recurrent or progressive disease is objectively documented or to death due to multiple myeloma, assessed every 4 weeks","title":"DOR (Duration of Response)","type":"SECONDARY"}